{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:47:45Z","timestamp":1775058465931,"version":"3.50.1"},"reference-count":19,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["etj.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,28]]},"abstract":"<jats:sec>\n<jats:title>Background and objective<\/jats:title>\n<jats:p>Lenvatinib showed promising results in a subgroup of patients with poorly differentiated thyroid carcinoma (PDTC) in the SELECT trial. Our aim was to report the effectiveness and tolerability of lenvatinib in our series of PDTC patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Medical records of eight consecutive patients with PDTC treated with lenvatinib in a single center between January 2019 and October 2022 were retrospectively reviewed. Inclusion criteria were PDTC diagnosis based on Turin criteria and evidence of disease progression in the previous 6 months.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Eight PDTC patients received an average dose of lenvatinib of 18.1 mg for a median duration of treatment of 10.3 months. The baseline Eastern Cooperative Oncology Group performance status was \u22652 in 50% of patients. Two patients had unresectable primary tumor. Seven patients showed extrathyroidal disease, particularly mediastinal lymph nodes (85.7%), lung (71.4%), and bone (71.4%). The disease control rate was 100%, with partial response and stable disease in 12.5 and 87.5%, respectively. The median time to best overall response was 3 months, and the median duration of response was 7.5 months. Median progression-free survival was 12 months and median overall survival was not reached. At 6, 12, and 18 months, overall survival was 87.5, 71.4, and 57.1%, respectively. All patients experienced drug-related adverse effects (AEs). Four (50%) had dose reductions and two (25%) had temporary treatment interruptions. Lenvatinib was stopped in two patients due to grade \u22653 AEs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Lenvatinib is an effective treatment for real-world PDTC patients. Adequate management of comorbidities and AEs increases treatment tolerability and minimizes dose reductions.<\/jats:p>\n<\/jats:sec>","DOI":"10.1530\/etj-23-0003","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T16:40:27Z","timestamp":1678380027000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma"],"prefix":"10.1530","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1191-4997","authenticated-orcid":true,"given":"Jo\u00e3o","family":"Roque","sequence":"first","affiliation":[{"name":"Endocrinology, Diabetes and Metabolism Department, Centro Hospitalar Universit\u00e1rio Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal"}]},{"given":"Tiago","family":"Nunes Silva","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetes and Metabolism Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"},{"name":"NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas of Universidade NOVA de Lisboa, Lisbon, Portugal"},{"name":"Unidade Investiga\u00e7\u00e3o Patobiologia Molecular, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"}]},{"given":"Catarina","family":"Regala","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetes and Metabolism Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-4106","authenticated-orcid":true,"given":"Ricardo","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Unidade Investiga\u00e7\u00e3o Patobiologia Molecular, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"}]},{"given":"Valeriano","family":"Leite","sequence":"additional","affiliation":[{"name":"Endocrinology, Diabetes and Metabolism Department, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"},{"name":"NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas of Universidade NOVA de Lisboa, Lisbon, Portugal"},{"name":"Unidade Investiga\u00e7\u00e3o Patobiologia Molecular, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Thyroid","first-page":"311","article-title":"Poorly differentiated carcinoma of the thyroid gland: current status and future prospects","volume":"29","author":"Ibrahimpasic","year":"2019","unstructured":"Ibrahimpasic TGhossein RShah JP & Ganly I. Poorly differentiated carcinoma of the thyroid gland: current status and future prospects. Thyroid201929311\u2013321. (https:\/\/doi.org\/10.1089\/thy.2018.0509)"},{"key":"bib2","series-title":"World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Endocrine Organs","author":"DeLellis","year":"2004","unstructured":"DeLellis RALloyd RV & Heitz PUWorld Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Endocrine Organs. Lyon, France: IARC Press2004."},{"key":"bib3","series-title":"American Journal of Surgical Pathology","first-page":"1256","article-title":"Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach","volume":"31","author":"Volante","year":"2007","unstructured":"Volante MCollini PNikiforov YESakamoto AKakudo KKatoh RLloyd RVLiVolsi VAPapotti MSobrinho-Simoes M, Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. American Journal of Surgical Pathology2007311256\u20131264. (https:\/\/doi.org\/10.1097\/PAS.0b013e3180309e6a)"},{"key":"bib4","series-title":"European Thyroid Journal","article-title":"Poorly differentiated thyroid carcinoma\u202f: a clinician\u2019s perspective","volume":"11","author":"Tong","year":"2022","unstructured":"Tong JRuan MJin YFu HCheng LLuo QLiu ZLv Z & Chen L. Poorly differentiated thyroid carcinoma\u202f: a clinician\u2019s perspective. European Thyroid Journal202211 e220021. (https:\/\/doi.org\/10.1530\/ETJ-22-0021)"},{"key":"bib5","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1245","article-title":"Outcomes in patients with poorly differentiated thyroid carcinoma","volume":"99","author":"Ibrahimpasic","year":"2014","unstructured":"Ibrahimpasic TGhossein RCarlson DLNixon IPalmer FLShaha ARPatel SGTuttle RMShah JP & Ganly I. Outcomes in patients with poorly differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism2014991245\u20131252. (https:\/\/doi.org\/10.1210\/jc.2013-3842)"},{"key":"bib6","series-title":"World Journal of Surgery","first-page":"934","article-title":"An evidence-based review of poorly differentiated thyroid cancer","volume":"31","author":"Sanders","year":"2007","unstructured":"Sanders EMLiVolsi VABrierley JShin J & Randolph GW. An evidence-based review of poorly differentiated thyroid cancer. World Journal of Surgery200731934\u2013945. (https:\/\/doi.org\/10.1007\/s00268-007-9033-3)"},{"key":"bib7","series-title":"Wiener Klinische Wochenschrift","first-page":"267","article-title":"Results of combined modality treatment in poorly differentiated and anaplastic thyroid carcinoma","volume":"102","author":"Auersperg","year":"1990","unstructured":"Auersperg MUs-Krasovec MPetric GPogacnik A & Besic N. Results of combined modality treatment in poorly differentiated and anaplastic thyroid carcinoma. Wiener Klinische Wochenschrift1990102267\u2013270."},{"key":"bib8","series-title":"Lancet. Oncology","first-page":"1126","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","unstructured":"Brose MSRobinson BSherman SIKrajewska JLin CCVaisman FHoff AOHitre EBowles DWHernando J, Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Oncology2021221126\u20131138. (https:\/\/doi.org\/10.1016\/S1470-2045(2100332-6)"},{"key":"bib9","series-title":"Lancet","first-page":"319","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","unstructured":"Brose MSNutting CMJarzab BElisei RSiena SBastholt Lde la Fouchardiere CPacini FPaschke RShong YK, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet2014384319\u2013328. (https:\/\/doi.org\/10.1016\/S0140-6736(1460421-9)"},{"key":"bib10","series-title":"New England Journal of Medicine","first-page":"621","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","unstructured":"Schlumberger MTahara MWirth LJRobinson BBrose MSElisei RHabra MANewbold KShah MHHoff AO, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New England Journal of Medicine2015372621\u2013630. (https:\/\/doi.org\/10.1056\/NEJMoa1406470)"},{"key":"bib11","series-title":"Endocrine","first-page":"462","article-title":"Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival","volume":"72","author":"De Leo","year":"2021","unstructured":"De Leo SDi Stefano MPersani LFugazzola L & Colombo C. Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival. Endocrine202172462\u2013469. (https:\/\/doi.org\/10.1007\/s12020-020-02477-0)"},{"key":"bib12","series-title":"Thyroid","first-page":"72","article-title":"Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice","volume":"28","author":"Berdelou","year":"2018","unstructured":"Berdelou ABorget IGodbert YNguyen TGarcia MEChougnet CNFerru ABuffet CChabre OHuillard O, Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid20182872\u201378. (https:\/\/doi.org\/10.1089\/thy.2017.0205)"},{"key":"bib13","series-title":"Endocrine","first-page":"358","article-title":"Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution","volume":"73","author":"Porcelli","year":"2021","unstructured":"Porcelli TLuongo CSessa FKlain MMasone STroncone GBellevicine CSchlumberger M & Salvatore D. Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution. Endocrine202173358\u2013366. (https:\/\/doi.org\/10.1007\/s12020-021-02634-z)"},{"key":"bib14","series-title":"Journal of the Endocrine Society","first-page":"bvac048","article-title":"Lenvatinib therapy for advanced thyroid cancer: real-life data on safety, efficacy, and some rare side effects","volume":"6","author":"Hamidi","year":"2022","unstructured":"Hamidi SBoucher ALemieux BRondeau GLeboef RSte-Marie LGLe XK & Mircescu H. Lenvatinib therapy for advanced thyroid cancer: real-life data on safety, efficacy, and some rare side effects. Journal of the Endocrine Society20226bvac048. (https:\/\/doi.org\/10.1210\/jendso\/bvac048)"},{"key":"bib15","series-title":"Advances in Therapy","first-page":"3850","article-title":"Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan","volume":"37","author":"Takahashi","year":"2020","unstructured":"Takahashi STahara MIto KTori MKiyota NYoshida KSakta Y & Yoshida A. Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan. Advances in Therapy2020373850\u20133862. (https:\/\/doi.org\/10.1007\/s12325-020-01433-8)"},{"key":"bib16","series-title":"Endocrine","first-page":"142","article-title":"Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina","volume":"69","author":"Jerkovich","year":"2020","unstructured":"Jerkovich FCalifano IBueno FCarrera JMGiglio RAbelleira E & Pitoia F. Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina. Endocrine202069142\u2013148. (https:\/\/doi.org\/10.1007\/s12020-020-02290-9)"},{"key":"bib17","series-title":"Thyroid","first-page":"91","article-title":"Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study","volume":"33","author":"Kim","year":"2023","unstructured":"Kim MJin MJeon MJKim EYShin DSLim DJKim BHKang HKim WBShong YK, Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study. Thyroid20233391\u201399. (https:\/\/doi.org\/10.1089\/thy.2022.0054)"},{"key":"bib18","series-title":"Thyroid","first-page":"732","article-title":"Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: A multicenter study in Korea","volume":"30","author":"Song","year":"2020","unstructured":"Song EKim MKim EYKim BHShin DYKang HCAhn BCKim WBShong YKJeon MJ, Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: A multicenter study in Korea. Thyroid202030732\u2013738. (https:\/\/doi.org\/10.1089\/thy.2019.0476)"},{"key":"bib19","series-title":"European Journal of Cancer","first-page":"228","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","unstructured":"Eisenhauer EATherasse PBogaerts JSchwartz LHSargent DFord RDancey JArbuck SGwyther SMooney M, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer200945228\u2013247. (https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026)"}],"container-title":["European Thyroid Journal"],"original-title":[],"link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/12\/2\/ETJ-23-0003.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/12\/2\/ETJ-23-0003.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/12\/2\/ETJ-23-0003.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T15:37:56Z","timestamp":1715873876000},"score":1,"resource":{"primary":{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/12\/2\/ETJ-23-0003.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":19,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/etj-23-0003","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}